Malignant Neoplastic Disease clinical trials at UCSF
1 research study open to eligible people
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of Avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
San Francisco, California and other locations
Our lead scientists for Malignant Neoplastic Disease research studies include Collin Blakely, MD.